Background: Roles of Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) in breast cancer remain unclear. Previously, ER-β1 and SRAP expression were found positively correlated in breast cancer and, therefore, expression of these two molecules could characterize cancers with a distinct clinical outcome.
introduction
Estrogen receptor beta's (ER-β) role in breast cancer remains unclear [1, 2] . Often higher levels of ER-β are associated with a better prognosis in tamoxifen-treated patients. Since most of the patients treated with tamoxifen are ER-positive (here referred to as ER-α-positive) tumors, little opportunity exists to determine the value of ER-β expression alone for its prognostic and/or predictive value with hormonal therapies, despite consistent observations, that approximately 5%-10% of ER-α-negative tumors show responses to tamoxifen [3, 4] . Analyses from the Early Breast Cancer Trialists Collaborative Group (EBCTCG 1998) suggested that there might be a small (6%) reduction in mortality for patients with 'ER poor' tumors receiving tamoxifen [5] , but this was no longer evident in later meta-analyses including more trials [6, 7] . With the discovery of ER-β expression alone in breast tumors representing ∼17% of primary breast cancers [8, 9] , the possibility now exists that, in this ER-negative cohort, tamoxifen could mediate activity via ER-β1, the full-length ligand-binding receptor isoform. Other isoforms, e.g. ER-β2/cx, are C-terminally truncated and do not bind ligand [1, 2] . Importantly, in studies determining ER-β expression in ER-α-negative cancers, a consistent finding is a positive association of ER-β1 expression with Ki67, a marker of proliferation [10] [11] [12] . Recently two studies published analyses on ER-β expression in tamoxifen-treated ER-α-negative patients [13, 14] and concluded that high ER-β expression in tamoxifen-treated ER-α-negative patients associated with a better clinical outcome. Both studies had relatively small numbers of cases and all patients were treated with tamoxifen; so only prognostic value was concluded. We recently observed that steroid receptor RNA activator protein (SRAP), a regulator of ER activity [15] [16] [17] , could be a prognostic marker in ER-α-positive breast tumors [18] . In this cohort [18] , we also noted that expression of SRAP correlated with ER-β1 expression, leading us to hypothesize that cases expressing both biomarkers might represent a specific tumor subset.
Here, we investigated ER-β1 and SRAP expression in tissues from a randomized, placebo-controlled trial to determine the benefit of tamoxifen added to chemotherapy of early breast cancer (EBC) in premenopausal women, NCIC-CTG-MA12 [19] .
methods patients
The patient population, treatment design and research focus for NCIC-CTG-MA12 were previously published [19] . A unique aspect of NCIC-CTG-MA12 was the eligibility of patients with ER-negative tumors for a study evaluating the benefit of tamoxifen therapy. At the time of initiation of NCIC-CTG-MA12 (1992), a potential benefit in patients with ERnegative tumors had not been excluded [5] . ER/progesterone receptor (PR) status was previously defined [19] . Tumors from this cohort were recently assessed for the frequency of intrinsic molecular subtypes as determined by the PAM50 assay and were ∼37% luminal A, ∼20% luminal B, ∼22% HER-2-enriched and ∼21% basal-like [20] .
Tissue microarrays (TMA), immunohistochemistry (IHC) and quantification of ER-β1 and SRAP are described in supplementary data, available at Annals of Oncology online [21] [22] [23] .
statistical analysis
Clinical end points in this analysis are as defined in NCIC-CTG-MA12 [19] . Relapse-free survival (RFS) was defined as time from randomization to earliest date of recurrence or death or censored on the last date the patient was known to be alive, and overall survival (OS) as the time from randomization to date of death or censored on the last date the patient was known to be alive. Both RFS and OS by expression and treatment status were described by Kaplan-Meier curves and compared by multivariate Cox models adjusting for treatment (when appropriate), age, performance status, time from diagnosis to randomization, nodal status, t-stage, receptor status and type of chemotherapy. Tumor grade was not assessed in the original data collection and retrospective assessment resulted in a large portion of missing values. It was not found to be an independent prognostic factor [20] . Therefore, it was not included in multivariate Cox models. Multivariate Cox models with the same covariates and an interaction term between treatment and expression status were used to assess predictive significance of markers. All statistical tests were two sided. [10, 18, 24] , ER-β1 and SRAP expression were significantly associated (Spearman coefficient r = 0.314, P < 0.0001, n = 449) in this trial cohort. When tumors were dichotomized according to low or high ER-β1, there were significant differences in SRAP expression (median SRAP IHC score 70 versus 83, Mann-Whitney P < 0.0001).
association of marker with clinical outcomes
There were no associations of ER-β1 or SRAP with either OS or RFS in the whole patient cohort regardless of treatment (supplementary Table S2 , available at Annals of Oncology Figure 1 . Expression of high levels of both ER-β1 and SRAP is predictive of response to tamoxifen in the entire NCIC-CTG-MA12 cohort assessed. Kaplan-Meier curves for OS (left-hand panels) and RFS (right-hand panels) in tamoxifen-treated (filled lines) versus placebo controls (dotted line), in patients with high levels of both ER-β1 and SRAP (top panels) compared with those with low levels in either ER-β1 or SRAP (bottom panels). predictive analysis in the whole patient cohort
As summarized in Table 1 , patients with high ER-β1 expression when treated with tamoxifen had better OS [adjusted hazard ratio (HR) of tamoxifen to placebo 0.45 with 95% confidence interval (CI) 0.22-0.90, P = 0.02]. As well, patients who received tamoxifen and whose tumors had either high ER-β1 or high SRAP had better RFS (adjusted HR of tamoxifen to placebo 0.36 with 95% CI 0.20-0.65, P = 0.0007 for women with high ER-β1 and 0.49 with 95% CI 0.29-0.84, P = 0.009 for women with high SRAP). In patients with low ER-β1 or SRAP expression, no significant difference was found between tamoxifen and placebo in either RFS or OS. Therefore, while neither ER-β1 nor SRAP were prognostic markers, these data suggest that they might be predictive markers for tamoxifen treatment benefit. The test of interaction between tamoxifen treatment and the marker, however, was not significant for either ER-β1 or SRAP (Table 1) . Due to the positive relationship between ER-β1 and SRAP, an analysis was undertaken to determine whether the detection of high levels of both these biomarkers together would be associated with the benefit of tamoxifen treatment. Data in Table 1 and Figure 1 suggest that, when considering all patients, women with high levels of both ER-β1 and SRAP benefited from tamoxifen treatment, while women with low levels of ER-β1 or SRAP did not. Specifically, the HR in OS between tamoxifen and placebo groups was 0.40 (95% CI 0.18-0.89; P = 0.03) for those with both high ER-β1 and SRAP (n = 120) and 1.03 (95% CI 0.66-1.60; P = 0.90) for those with either low ER-β1 or SRAP (n = 329), and the HR in RFS between tamoxifen and placebo groups was 0.28 (95% CI 0.14-0.56; P = 0.0003) for those with both high ER-β1 and SRAP (n = 120) and 0.88 (95% CI 0.60-1.30; P = 0.53) for those with either low ER-β1 or SRAP (n = 329). The interaction tests for OS and RFS were both significant (P = 0.03 and 0.01, respectively). These data lend further support to the possibility that high ER-β1 and SRAP are predictive markers for the benefit of tamoxifen treatment in this cohort of breast cancer patients [19] .
predictive analysis stratified by ER status
Since patients with both ER-α-positive or -negative tumors were recruited into NCIC-CTG-MA12, a subgroup analysis was undertaken stratifying cases by ER-α status.
In ER-α-positive tumors, levels of ER-β1 and SRAP expression, alone or together, were not predictive of treatment benefit from tamoxifen (Table 1) .
In ER-α-negative tumors with high ER-β1 expression, a longer RFS was observed for tamoxifen-treated patients than those receiving placebo (adjusted HR = 0.22, 95% CI 0.09-0.54, P = 0.0009, Table 1 ). The interaction value between expression of ER-β1 and treatment in RFS was also significant, P = 0.03 (Table 1) . Similarly, a longer OS was observed for those patients with high levels of ER-β1 and treated with tamoxifen (adjusted HR = 0.27, 95% CI 0.11-0.70, P = 0.007, Table 1 ). The interaction was not significant (P = 0.10). There was evidence that, in ER-α-negative placebo patients, high ER-β1 levels in tumors were associated with worse outcome since the HR for low versus high ER-β1-expressors was 0.23 (95% CI 0.09-0.61, P = 0.003) for OS and for RFS was 0.23 (95% CI 0.09-0.57, P = 0.002), implying that ER-β1 was also prognostic for ER-α-negative patients.
Similarly, in the ER-α-negative cohort, high SRAP expression was associated with a longer RFS in patients treated with tamoxifen (RFS, adjusted HR = 0.23, 95% CI 0.09-0.61, P = 0.003) compared with those receiving placebo. The interaction test for predictive analysis was significant, P = 0.02 (Table 1) .
Importantly, high expression of both SRAP and ER-β1 was predictive for the benefit of tamoxifen treatment (interaction test P = 0.02, Table 1 and Figure 2 ).
These data suggest that high expression of ER-β1 especially when combined with high SRAP expression is a predictive marker for the benefit of tamoxifen treatment primarily in ER-α-negative EBC.
discussion
Results of this study suggest that high expression of both ER-β1 and SRAP is predictive of better clinical outcome to tamoxifen treatment in premenopausal women previously treated with chemotherapy. The surprising finding was that most benefit was found in ER-α-negative breast cancer. This study is the first to provide evidence that ER-β1 expression particularly when co-expressed with high SRAP levels is predictive of the efficacy of adjuvant tamoxifen treatment in ER-α-negative breast cancer in premenopausal women previously treated with chemotherapy.
With regard to ER-β1 expression, the current study is consistent with and adds valuable new information to the conclusions of two recently published studies (non-placebo control, non-randomized) where the relationship of ER-β expression and clinical outcome was determined in ER-α-negative tamoxifen-treated breast cancer [13, 14] . Our study, like that of Honma et al. [13] , specifically measured ER-β1, the ligand-binding ER-β isoform. The data support the hypothesis 
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that tamoxifen effects might be mediated in ER-α-negative breast cancers, at least in part, through ER-β1 within the tumor cells and not through alternative, non-ER-mediated activities [25] . Effects through ER-positive immune and endothelial cells present within the heterogeneous cellular composition of any breast tumor in vivo cannot be excluded [26] [27] [28] .
Previously small subsets of patients with apparently ER-α-negative breast cancer were reported to respond to tamoxifen treatment [3, 4] . The reasons behind such apparently paradoxical observations remain unknown [29, 30] , although false negative assays for technical reasons or ER-independent tamoxifen action [30] have been suggested. However, a role of ER-β1 in this group of so-called ER-negative cancers is now a possibility. In ER-α-negative tumors, correlations of ER-β1 with Ki67, a proliferation marker, were found [10] [11] [12] , suggesting that ER-β1 may have a role in driving proliferation of these tumors, and that tamoxifen treatment, through inhibiting ER-β1 activity [31] , could slow the progression of such tumors. This has important implications since an already approved treatment of breast cancer which is mostly well tolerated, has a low cost, is orally administered and has over 30 years of clinical use, may be an attractive alternative for a group of patients with generally few options other than cytotoxic therapies.
A confounding issue associated with the MA12-trial is suboptimal treatment compliance in both tamoxifen treated and placebo arms [19] . This may underlie results showing a marginal benefit from tamoxifen in the whole population with no evidence of greater benefit for ER-α-positive compared with the ER-α-negative subgroup. Furthermore, it may in part be the reason that we only saw a trend towards high ER-β1 levels being associated with better RFS in all patients treated with tamoxifen irrespective of ER-α status.
The present study population was not representative of the normal breast cancer population since the MA12-trial focused on premenopausal women. However, at the molecular level, the cases did represent the 'usual' population, i.e. cases represented on the TMA were 65% ER-α-positive and 35% ER-α-negative, but when receptor positivity was expanded to include those which were ER-α-negative but PR+, the receptorpositive population became 74%. Furthermore, analysis of frequency of intrinsic molecular subtypes using the 50 gene subtype predictor, PAM50, suggested that the MA-12 breast cancer cohort is similar to the usual population [20] .
The positive relationship found between SRAP and ER-β1 is interesting and may have a mechanistic basis. SRAP physically interacts with both ER-α and ER-β1 and affects activity [15] [16] [17] . As well, altering SRAP expression in breast cancer cells resulted in altered expression of several genes, including ER-β [32] . Furthermore, our unpublished data suggest that over-expressed ER-β1 in MCF7 breast cancer cells may bind to sequences in the SRA-gene promoter under some conditions, suggesting potential regulatory interactions of the two genes in breast cancer. This requires further investigation since our results show that combined assessment of ER-β1 and SRAP expression in a tumor provided better predictive information than measurement of either alone. If a regulatory relationship exists between ER-β1 and SRAP, this may be analogous to measurement of PR a downstream marker of ER-α-signaling in traditionally ER+ breast cancer [33, 34] . It is also possible that ER-β1 and SRAP expression are associated with the luminal molecular subtype of breast cancer, which was shown to predict better clinical outcome to tamoxifen [20, 35] . Interestingly, ER-β1 seems to localize evenly across the main intrinsic subtypes of breast cancer [36] , but using multiple correspondence analysis, ER-β1 expression in node-positive cases was associated with classically ER-negative cancers with more aggressive clinical outcomes [36] .
In conclusion, our data together with those reported in two other studies support the exciting possibility that ER-β1 may be a treatment target in some ER-negative breast cancers. This deserves further study and if true, means that a group of patients previously considered only for aggressive chemotherapies would now be candidates for better tolerated hormonal-like therapies.
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